Thursday, November 7, 2013

Cost-effective method accurately orders DNA sequencing along entire chromosomes

Cost-effective method accurately orders DNA sequencing along entire chromosomes


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

7-Nov-2013



[


| E-mail

]


Share Share

Contact: Leila Gray
leilag@uw.edu
206-685-0381
University of Washington



A major step toward improving the quality of rapid, inexpensive genome assembly



A new computational method has been shown to quickly assign, order and orient DNA sequencing information along entire chromosomes. The method may help overcome a major obstacle that has delayed progress in designing rapid, low-cost -- but still accurate -- ways to assemble genomes from scratch. Data gleaned through this new method can also validate certain types of chromosomal abnormalities in cancer, research findings indicate.


The advance was reported in Nature Biotechnology by several University of Washington scientists led by Dr. Jay Shendure, associate professor of genome sciences.


Existing technologies can quickly produce billions of "short reads" of segments of DNA at very low cost. Various approaches are currently used to put the pieces together to see how DNA segments line up to form larger stretches of the genetic code.


However, current methods produce a highly fragmented genome assembly, lacking long-range information about what sequences are near what other sequences, making further biological analysis difficult.


"Genome science has remained remarkably distant from routinely assembling genomes to the standards set by the Human Genome Project," said the researchers. They noted that the Human Genome Project tapped into many different techniques to achieve its end result. Many of these are too expensive, technically difficult, and impractical for large-scale initiatives such as the Genome 10K Project, which aims to sequence and assemble the genomes of 10,000 vertebrate species.


Members of the Shendure lab that developed what they hope will be a more scalable strategy were Joshua N. Burton, Andrew Adey, Rupali P. Patwardhan, Ruolan Qiu, and Jacob O. Kitzman.


To more completely assemble genomes, they tapped into a technology called Hi-C, which measures the three-dimensional architecture and physical territories of chromosomes within the nuclei of cells. Hi-C maps the physical interactions between regions of the chromosomes in a genome, including contact within a chromosome and with other chromosomes. The results indicate which regions tend to occur near each other within three-dimensional space in a cell's nucleus.


The researchers speculated that this interaction data, because it offers clues about the position of and distances between various regions of the chromosome, might reveal how DNA sequences are grouped and lined up along entire chromosomes. They wondered if the interaction data could show them which regions of the genome are near each other on each chromosome.


Their investigation of this possibility led them to create what they named LACHESIS (an acronym for "ligating adjacent chromatin enables scaffolding in situ"). The map of physical interactions generated by Hi-C was interpreted by the LACHESIS computational program to assign, order and orient genomic sequences into their correct position along chromosomes, including DNA positioned close to the centromere, the "pinch waist" gap in the chromosome shape.


The researchers combined their new approach with other cheap and widely used sequencing methods to generate chromosome-scale assemblies of the human, mouse and fruit fly genomes. The researchers were able to cluster nearly all scaffolds -- collections of short DNA segments whose position relative to each other is unknown -- into groups that corresponded to individual chromosomes.


They then ordered and oriented the scaffolds assigned to each chromosome group, and validated their results by comparing them to the high-quality reference genomes for these species that were generated by the Human Genome Project. In the case of human genomes, they achieved 98 percent accuracy in assigning tens of thousands of sequences of contiguous DNA to chromosome groups and 99 percent accuracy in ordering and orienting these sequences within chromosome groups.


"We think the method may fundamentally change how we approach the assembly of new genomes with next-generation sequencing technologies," noted Shendure.


While he and his team cite many areas in which the computational and experimental methods can be improved, the approach is an important step in his lab's long-term goal to facilitate the assembly, for a variety of species, of low-cost, high-quality genomes that meet the rigorous standards set by the Human Genome Project.


###


The research was supported by grants HG006283 and T32HG000035 from the National Human Genome Research Institute, and graduate research fellowships from the National Science Foundation.




[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Cost-effective method accurately orders DNA sequencing along entire chromosomes


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

7-Nov-2013



[


| E-mail

]


Share Share

Contact: Leila Gray
leilag@uw.edu
206-685-0381
University of Washington



A major step toward improving the quality of rapid, inexpensive genome assembly



A new computational method has been shown to quickly assign, order and orient DNA sequencing information along entire chromosomes. The method may help overcome a major obstacle that has delayed progress in designing rapid, low-cost -- but still accurate -- ways to assemble genomes from scratch. Data gleaned through this new method can also validate certain types of chromosomal abnormalities in cancer, research findings indicate.


The advance was reported in Nature Biotechnology by several University of Washington scientists led by Dr. Jay Shendure, associate professor of genome sciences.


Existing technologies can quickly produce billions of "short reads" of segments of DNA at very low cost. Various approaches are currently used to put the pieces together to see how DNA segments line up to form larger stretches of the genetic code.


However, current methods produce a highly fragmented genome assembly, lacking long-range information about what sequences are near what other sequences, making further biological analysis difficult.


"Genome science has remained remarkably distant from routinely assembling genomes to the standards set by the Human Genome Project," said the researchers. They noted that the Human Genome Project tapped into many different techniques to achieve its end result. Many of these are too expensive, technically difficult, and impractical for large-scale initiatives such as the Genome 10K Project, which aims to sequence and assemble the genomes of 10,000 vertebrate species.


Members of the Shendure lab that developed what they hope will be a more scalable strategy were Joshua N. Burton, Andrew Adey, Rupali P. Patwardhan, Ruolan Qiu, and Jacob O. Kitzman.


To more completely assemble genomes, they tapped into a technology called Hi-C, which measures the three-dimensional architecture and physical territories of chromosomes within the nuclei of cells. Hi-C maps the physical interactions between regions of the chromosomes in a genome, including contact within a chromosome and with other chromosomes. The results indicate which regions tend to occur near each other within three-dimensional space in a cell's nucleus.


The researchers speculated that this interaction data, because it offers clues about the position of and distances between various regions of the chromosome, might reveal how DNA sequences are grouped and lined up along entire chromosomes. They wondered if the interaction data could show them which regions of the genome are near each other on each chromosome.


Their investigation of this possibility led them to create what they named LACHESIS (an acronym for "ligating adjacent chromatin enables scaffolding in situ"). The map of physical interactions generated by Hi-C was interpreted by the LACHESIS computational program to assign, order and orient genomic sequences into their correct position along chromosomes, including DNA positioned close to the centromere, the "pinch waist" gap in the chromosome shape.


The researchers combined their new approach with other cheap and widely used sequencing methods to generate chromosome-scale assemblies of the human, mouse and fruit fly genomes. The researchers were able to cluster nearly all scaffolds -- collections of short DNA segments whose position relative to each other is unknown -- into groups that corresponded to individual chromosomes.


They then ordered and oriented the scaffolds assigned to each chromosome group, and validated their results by comparing them to the high-quality reference genomes for these species that were generated by the Human Genome Project. In the case of human genomes, they achieved 98 percent accuracy in assigning tens of thousands of sequences of contiguous DNA to chromosome groups and 99 percent accuracy in ordering and orienting these sequences within chromosome groups.


"We think the method may fundamentally change how we approach the assembly of new genomes with next-generation sequencing technologies," noted Shendure.


While he and his team cite many areas in which the computational and experimental methods can be improved, the approach is an important step in his lab's long-term goal to facilitate the assembly, for a variety of species, of low-cost, high-quality genomes that meet the rigorous standards set by the Human Genome Project.


###


The research was supported by grants HG006283 and T32HG000035 from the National Human Genome Research Institute, and graduate research fellowships from the National Science Foundation.




[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Source: http://www.eurekalert.org/pub_releases/2013-11/uow-cma110713.php
Similar Articles: eminem   aapl   Dakota Johnson   911 Memorial   us open tennis  

Hangouts 2.0 now rolling out with SMS support

Hangouts

New version lets you use Google's IM app to send and receive texts

As promised at last week's Google+ event, the new version of Hangouts capable of sending and receiving text messages is now rolling out through Google Play. The update to brings things up to speed with the version of Hangouts on the Nexus 5, which is the default SMS app on that device. When you first load up the updated Hangouts you'll be presented with a fullscreen message asking if you want to enable SMS support — tap yes and your messages are imported into the app, and you'll receive future SMS notifications through Hangouts instead of your preloaded SMS app. Tap "Maybe later" and things will stay as they are.

For the most part, the texting experience through Hangouts 2.0 on any other device is the same as it is on the Nexus 5 — SMS conversations are shown in a list alongside your other, and you can choose whether you want to communicate over Hangouts or SMS when starting a new conversation. Want out? At any point you can go to Settings > SMS > Turn on SMS to enable or disable SMS in Hangouts.

The update also adds animated GIF support and a new location-sharing button, which you can tap to tell contacts where you are.

As usual the update is being rolled out gradually across the Android user base, so don't be surprised if you don't see it immediately. If you're updating today, be sure to hit the comments and let us know whether you're opting into SMS in Hangouts or not.


    






Source: http://feedproxy.google.com/~r/androidcentral/~3/V5rJQvS01WI/story01.htm
Similar Articles: ufc   christopher columbus   ricin   Derrick Thomas   lesean mccoy  

'Hunger Games: Catching Fire': The 8 Jams We've Heard So Far


MTV News wraps up what we've heard from film's soundtrack.


By Brenna Ehrlich








Source:
http://www.mtv.comhttp://www.mtv.com/news/articles/1717062/hunger-games-cathing-fire-soundtrack-what-we-know-so-far.jhtml

Tags: brandon marshall   mariano rivera   Anna Gunn   anthony weiner   beyonce  

Hope builds for a drug that might shut down a variety of cancers

Hope builds for a drug that might shut down a variety of cancers


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

7-Nov-2013



[


| E-mail

]


Share Share

Contact: Sarah Smith
sas2072@med.cornell.edu
646-317-7401
Weill Cornell Medical College



Cancer cells 'go to sleep' when crucial set of molecules is targeted




NEW YORK (November 7, 2013) -- The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53. Targeting these enzymes with novel agents might prevent the growth of p53 mutant cancers, thereby benefiting a broad spectrum of cancer patients, including those with breast, ovarian, lung, colorectal and brain tumors.


In the Nov. 7 issue of Cell, investigators pinpoint two cellular enzymes -- Type 2 phosphatidylinositol-5-phosphate 4-kinases α and β (Type 2 PIP kinases) -- as essential for cancer growth when cells have lost p53, the powerful tumor-suppressor gene long dubbed the "guardian of the genome." More than half of all cancers lose this gene, allowing these cancers to grow at will.


The researchers discovered that the Type 2 PIP kinases are not critical for the growth of normal cells but become essential for cell growth when p53 is lost due to mutations or deletions. The scientists showed, in animal and lab studies of human cancer cells, that targeting these molecules effectively shuts down the growth of p53 mutant cancers.


Although the studies were conducted in human breast cancer cells, the researchers believe Type 2 PIP kinase inhibitors could block the growth of cancers with a mutated or missing p53 gene.


"The fact that one can delete the Type 2 PIP kinases in normal human cells or in mice with essentially no effect on cell survival suggests that inhibitors of these enzymes should have little toxicity," says Dr. Cantley, the study's senior author and director of the Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.


Dr. Cantley is already leading an effort to develop drugs to shut down these kinases. "Well-designed Type 2 PIP kinase inhibitors may turn the tide on p53 mutant cancer," he says.


A Crucial Link


Dr. Cantley is known for his discovery of the PI 3-kinase oncogene, and pioneering work in teasing apart how the gene contributes to cancer. PI 3-kinases (PI3K) have been linked to a wide variety of cellular functions, including cell growth and proliferation, and most cancers activate PI3K by one or more mechanisms. Dr. Cantley's discovery led to promising avenues for the development of personalized cancer therapies.


Activity of PI3K is in some cases linked to Type 2 PIP kinases, so in this study, Dr. Cantley sought to understand the function of these enzymes. Because the researchers knew that a subset of breast cancers over-express these molecules, investigators looked at their role in HER2-positive breast cancers, which typically are more aggressive tumors.


The researchers, including those from Harvard Medical School, Beth Israel Deaconess Medical Center and other institutions, discovered that the enzymes are silent in cells that have healthy p53. One critical role of p53 is to "rescue" cells that are producing excess reactive oxygen species (ROS), which are byproducts of cells that are growing too rapidly. The oxidative stress produced by ROS can damage cell structures, so p53 attempts to reduce ROS in affected cells. "If, however, ROS levels exceed the capacity of p53s to rescue it, then p53 takes on a second function, which is to kill the cell," Dr. Cantley says.


"That is why cancers often disable p53. If p53 is mutated or gone, then the cell keeps on growing at a very high rate," he says. "And then ROS begins to damage genes, making the cancer even more aggressive."


The Type 2 PIP kinases are the backup rescue system to p53. But they only reduce ROS enough to keep the cells from dying. (Too much ROS will also kill a cell.)


What this means is that cancer cells become "absolutely dependent on these kinases to be able to grow," Dr. Cantley says.


Taking Advantage of "Synthetic Lethality"


But there is a big and important hitch in this scenario, he adds. If the Type 2 PIP kinases are inhibited, and if p53 is deactivated, the cancer cell essentially "goes to sleep," he says. "It just stops dividing and growing. This is called synthetic lethality: You can get by without one gene or another, but if you lose both of them nothing can grow."


Shutting down these enzymes, as the researchers did in their experiments, puts cancer cells to sleep but has no effect on healthy cells. "A normal cell doesn't need Type 2 PIP kinases at all, so inhibitors of these enzymes should not be toxic to humans," Dr. Cantley says.


Because it is not possible to replace p53 proteins or the gene in cells that have lost it (many attempts have been made), deactivating Type 2 PIP kinases is the next-best thing, he adds. "This would likely be a very powerful advance in the treatment of many cancers."


###


This work was supported by NIH grant R01 GM041890 and by a Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation (SU2C-AACR-DT0209).


Co-authors include first author Dr. Brooke M. Emerling, Gary Bellinger and Rayman Choo-Wing from Weill Cornell Medical College; Dr. George Poulogiannis, Kazumi S. Tsukazawa, Hye-Seok Shim, and Dr. Gina M. DeNicola from Harvard Medical School; Dr. Gerburg M. Wulf, Dr. John M. Asara, Xin Yuan, and Dr. Andrea Bullock from Beth Israel Deaconess Medical School; Dr. Jonathan B. Hurov from Agios Pharmaceuticals; Dr. Eric L. Bell from the Massachusetts Institute of Technology; Dr. Katja A. Lamia from The Scripps Research Institute; Dr. Lucia E. Rameh from Boston University School of Medicine; Dr. Atsuo T. Sasaki from the University of Cincinnati College of Medicine; Dr. Jiaxi Song, Dr. Victoria Brown, and Dr. Sabina Signoretti from Dr. Dana-Farber Cancer Institute.


Weill Cornell Medical College

Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.



Office of External Affairs

Weill Cornell Medical College

tel: 646.317.7401

email: pr@med.cornell.edu

Follow WCMC on Twitter and Facebook



[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Hope builds for a drug that might shut down a variety of cancers


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

7-Nov-2013



[


| E-mail

]


Share Share

Contact: Sarah Smith
sas2072@med.cornell.edu
646-317-7401
Weill Cornell Medical College



Cancer cells 'go to sleep' when crucial set of molecules is targeted




NEW YORK (November 7, 2013) -- The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53. Targeting these enzymes with novel agents might prevent the growth of p53 mutant cancers, thereby benefiting a broad spectrum of cancer patients, including those with breast, ovarian, lung, colorectal and brain tumors.


In the Nov. 7 issue of Cell, investigators pinpoint two cellular enzymes -- Type 2 phosphatidylinositol-5-phosphate 4-kinases α and β (Type 2 PIP kinases) -- as essential for cancer growth when cells have lost p53, the powerful tumor-suppressor gene long dubbed the "guardian of the genome." More than half of all cancers lose this gene, allowing these cancers to grow at will.


The researchers discovered that the Type 2 PIP kinases are not critical for the growth of normal cells but become essential for cell growth when p53 is lost due to mutations or deletions. The scientists showed, in animal and lab studies of human cancer cells, that targeting these molecules effectively shuts down the growth of p53 mutant cancers.


Although the studies were conducted in human breast cancer cells, the researchers believe Type 2 PIP kinase inhibitors could block the growth of cancers with a mutated or missing p53 gene.


"The fact that one can delete the Type 2 PIP kinases in normal human cells or in mice with essentially no effect on cell survival suggests that inhibitors of these enzymes should have little toxicity," says Dr. Cantley, the study's senior author and director of the Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.


Dr. Cantley is already leading an effort to develop drugs to shut down these kinases. "Well-designed Type 2 PIP kinase inhibitors may turn the tide on p53 mutant cancer," he says.


A Crucial Link


Dr. Cantley is known for his discovery of the PI 3-kinase oncogene, and pioneering work in teasing apart how the gene contributes to cancer. PI 3-kinases (PI3K) have been linked to a wide variety of cellular functions, including cell growth and proliferation, and most cancers activate PI3K by one or more mechanisms. Dr. Cantley's discovery led to promising avenues for the development of personalized cancer therapies.


Activity of PI3K is in some cases linked to Type 2 PIP kinases, so in this study, Dr. Cantley sought to understand the function of these enzymes. Because the researchers knew that a subset of breast cancers over-express these molecules, investigators looked at their role in HER2-positive breast cancers, which typically are more aggressive tumors.


The researchers, including those from Harvard Medical School, Beth Israel Deaconess Medical Center and other institutions, discovered that the enzymes are silent in cells that have healthy p53. One critical role of p53 is to "rescue" cells that are producing excess reactive oxygen species (ROS), which are byproducts of cells that are growing too rapidly. The oxidative stress produced by ROS can damage cell structures, so p53 attempts to reduce ROS in affected cells. "If, however, ROS levels exceed the capacity of p53s to rescue it, then p53 takes on a second function, which is to kill the cell," Dr. Cantley says.


"That is why cancers often disable p53. If p53 is mutated or gone, then the cell keeps on growing at a very high rate," he says. "And then ROS begins to damage genes, making the cancer even more aggressive."


The Type 2 PIP kinases are the backup rescue system to p53. But they only reduce ROS enough to keep the cells from dying. (Too much ROS will also kill a cell.)


What this means is that cancer cells become "absolutely dependent on these kinases to be able to grow," Dr. Cantley says.


Taking Advantage of "Synthetic Lethality"


But there is a big and important hitch in this scenario, he adds. If the Type 2 PIP kinases are inhibited, and if p53 is deactivated, the cancer cell essentially "goes to sleep," he says. "It just stops dividing and growing. This is called synthetic lethality: You can get by without one gene or another, but if you lose both of them nothing can grow."


Shutting down these enzymes, as the researchers did in their experiments, puts cancer cells to sleep but has no effect on healthy cells. "A normal cell doesn't need Type 2 PIP kinases at all, so inhibitors of these enzymes should not be toxic to humans," Dr. Cantley says.


Because it is not possible to replace p53 proteins or the gene in cells that have lost it (many attempts have been made), deactivating Type 2 PIP kinases is the next-best thing, he adds. "This would likely be a very powerful advance in the treatment of many cancers."


###


This work was supported by NIH grant R01 GM041890 and by a Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation (SU2C-AACR-DT0209).


Co-authors include first author Dr. Brooke M. Emerling, Gary Bellinger and Rayman Choo-Wing from Weill Cornell Medical College; Dr. George Poulogiannis, Kazumi S. Tsukazawa, Hye-Seok Shim, and Dr. Gina M. DeNicola from Harvard Medical School; Dr. Gerburg M. Wulf, Dr. John M. Asara, Xin Yuan, and Dr. Andrea Bullock from Beth Israel Deaconess Medical School; Dr. Jonathan B. Hurov from Agios Pharmaceuticals; Dr. Eric L. Bell from the Massachusetts Institute of Technology; Dr. Katja A. Lamia from The Scripps Research Institute; Dr. Lucia E. Rameh from Boston University School of Medicine; Dr. Atsuo T. Sasaki from the University of Cincinnati College of Medicine; Dr. Jiaxi Song, Dr. Victoria Brown, and Dr. Sabina Signoretti from Dr. Dana-Farber Cancer Institute.


Weill Cornell Medical College

Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.



Office of External Affairs

Weill Cornell Medical College

tel: 646.317.7401

email: pr@med.cornell.edu

Follow WCMC on Twitter and Facebook



[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Source: http://www.eurekalert.org/pub_releases/2013-11/wcmc-hbf110713.php
Tags: torrie wilson   bob newhart   notre dame   2020 Olympics   Robocop  

Scientists Found the Wolverine Healing Gene

Scientists Found the Wolverine Healing Gene

Deep within our bodies are all kinds of genes that turn on and off over the years, including the very genes that make you grow a body in the first place. This is where scientists are looking for the magical code that could enable us to regrow organs and regenerate limbs. A Harvard researcher thinks he might've found it.

Read more...


    






Source: http://feeds.gawker.com/~r/gizmodo/full/~3/vnr9m7gXeH4/scientists-found-the-wolverine-healing-gene-1460379380
Related Topics: boston red sox   Mexico vs Panama   Jeff Daniels   reggie bush   mark sanchez  

5 ways BYOD is shaking up tech support



November 07, 2013







Amid the clamor of "bring your own device" (BYOD), a question lurks in the background: "What happens to technical service and support?" Concerns for the tech support function encompass the extremes, from agents being overwhelmed with calls, to their becoming inhabitants of a help desk ghost town.


On the one hand, it’s easy to imagine a flood of calls as employees attempt to access wireless networks or synch their e-mail, especially in companies that permit the use of any device type. At the same time, as more people own smartphones, they are increasingly accustomed to resolving issues independently, through online forums, communities and other means of self-support.


By 2016, says Gartner analyst Jarod Greene, help desks will see a 25% to 30% drop in user-initiated call volume, as BYOD drives a companion trend of BYOS, or “bring your own support.”



To continue reading, register here to become an Insider


It's FREE to join




Source: http://www.infoworld.com/d/consumerization-of-it/5-ways-byod-shaking-tech-support-230379?source=rss_mobile_technology
Category: lesean mccoy   Eiza González  

Zaatari: Temporary city on desert's edge


"A Day in the Life" is a multi-part documentary joint venture between Yahoo News UK and the United Nations High Commission for Refugees.

The series and special features accompanying it depict daily existence in the Zaatari refugee camp in Jordan, where more than 122,000 people displaced by the Syrian civil war have fled.

Zaatari has grown to become Jordan's fourth largest city, spawning food markets, housewares shops and, some say, drug dealing and prostitution.

"A Day in the Life" video episodes will appear here as they debut.



Source: http://news.yahoo.com/zaatari-refugee-camp/
Tags: TSLA   LAX shooting   detroit lions   Miley Cyrus Pregnant   apple stock